Thane Wettig
Algemeen Directeur bij FIBROGEN, INC.
Vermogen: 458 547 $ op 30-04-2024
Actieve functies van Thane Wettig
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FIBROGEN, INC. | Directeur/Bestuurslid | 02-10-2023 | - |
| Algemeen Directeur | 23-07-2023 | - | |
| Corporate Officer/Principal | 22-06-2020 | 23-07-2023 |
Loopbaan van Thane Wettig
Eerdere bekende functies van Thane Wettig
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01-01-1990 | 01-01-2009 |
| Verkoop & Marketing | 01-01-2009 | - | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01-01-2018 | - |
Opleiding van Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Beurs
- Insiders
- Thane Wettig
- Ervaring
